Table 2.

Detailed description of 20 patients, who were treated with isavuconazole for a proven, probable or possible invasive mold infection

Age	Gender	Heme Malignancy	Chemotherapy 30 days before IVC	Antifungal 30 days before IVC	Allo- HCT	GvHD
76	Male	AML	Induction	PCZ, ECH
68	Male	MDS	Consolidation	FCZ	Yes	No
51	Female	AML	Induction	L-AMB
41	Female	MDS	Consolidation	PCZ	Yes	No
42	Male	AML	Induction	L-AMB
62	Female	AML	Induction	L-AMB
61	Male	ALL	Consolidation	L-AMB + ECH + VCZ	Yes	Yes
65	Male	AML	Consolidation	L-AMB	Yes	Yes
50	Female	MDS	Consolidation	PCZ	Yes	No
60	Male	AML	Salvage	PCZ	Yes	No
67	Male	AML	Induction	VCZ
70	Female	AML	Induction	VCZ
74	Male	AML	Induction	PCZ	Yes	No
17	Male	ALL	Consolidation	ECH	Yes	No
59	Female	Lymphoma	None	L-AMB	Yes	No
58	Male	MDS	None	PCZ, ECH	Yes	Yes
74	Female	MDS	Salvage	L-AMB + ECH
69	Male	AML	Induction	FCZ	Yes	No
43	Male	AML	Conditioning	L-AMB	Yes	Yes
53	Male	Lymphoma	Conditioning	L-AMB	Yes	No

Age	Gender	Neutropenia days before IVC	Neutropenia days after IVC	Treatment Type	IFI	Reason for IVC start	Reason of IVC stop	IVC days
76	Male	26	0	Targeted	Proven IA	Hepatotoxicity	Death	124
68	Male	21	4	Empirical	Possible IA	Renal insufficiency	No IFI	7
51	Female	19	30	Empirical	Possible IA	Simplification	AE (rash)	2
41	Female	0	0	Targeted	Proven IA	Neurotoxicity	Cost	9
42	Male	13	10	Targeted	Probable IA	Hepatotoxicity	Simplification	6
62	Female	8	15	Targeted	Probable IA	Simplification	Hematological disease progression	11
61	Male	0	0	Targeted	Proven mucormycosis	Better CNS penetration	AE (rash)	1
65	Male	0	0	Empirical	Possible IA	Hepatotoxicity, low PCZ level	Simplification	81
50	Female	0	0	Targeted	Proven IA	Long QTc	Death	4
60	Male	0	15	Targeted	Probable IA	Empirical	Hematological disease progression	20
67	Male	0	0	Targeted	Proven mucormycosis	Combination treatment	Ongoing	568
70	Female	0	0	Targeted	Probable IA	Hepatotoxicity	End of treatment	257
74	Male	30	10	Empirical	Possible IA	Renal insufficiency	Simplification	69
17	Male	0	0	Targeted	Proven IA	Simplification	End of treatment	270
59	Female	0	0	Empirical	Possible IA	Renal insufficiency	Cost	36
58	Male	0	0	Targeted	Proven cryptococcosis	Hepatotoxicity	Cost	127
74	Female	10	7	Targeted	Proven Mucormycosis	Combination treatment	Ongoing	151
69	Male	0	0	Targeted	Probable IA	Empirical	Hematological disease progression	165
43	Male	0	0	Targeted	Proven IA	Simplification	Ongoing	170
53	Male	30	0	Empirical	Possible IA	Simplification	No IFI	10

IVC Isavuconazole, HCT hematopoietic cell transplant, GvHD graft versus host disease, IFI invasive fungal infection, AML acute myelogenous leukemia, POS posaconazole, ECH echinocandin, IA invasive aspergillosis, MDS myelodysplastic syndrome, FCZ: fluconazole, L-AMB liposomal amphotericin-B, AE adverse event, VCZ voriconazole, ALL acute lymphoblastic leukemia, CNS central nervous system